ClinicalTrials.gg
RecruitingNCT06806085Updated Nov 20, 2026

Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained

An observational study in Small-incision Lenticule Extraction (SMILE) Surgery, Corneal Higher-order Wavefront Aberrations and Residual Lenticule, sponsored by Second Affiliated Hospital of Nanchang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Second Affiliated Hospital of Nanchang University · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
33
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Analysis of Influencing Factors of High-Order Aberrations of SMILE with Lenticule Retained

Read the detailed description

Wavefront analysis and other objective methods are the mainstream approaches for assessing visual quality after refractive surgery, with high-order aberrations being the main observation indicators. Some studies have explored the correlation between various complications after SMILE surgery and high-order aberrations. However, research on lenticule retained after surgery has mainly focused on clinical management and case reports of overt lenticule retained, while there is a lack of high-quality observational studies on the population with covert lenticule retained (periphery residual lenticule) to serve as evidence. This often puts clinicians in a dilemma of whether to perform another surgery to remove the remnants. In summary, although research on lenticule retained after SMILE surgery is gradually increasing, systematic studies on their relationship with higher-order aberrations are still insufficient. This study aims to fill the gap in existing research by comparing and analyzing high-order aberrations between patients with and without periphery residual lenticule, providing a more comprehensive assessment of postoperative visual quality. This will offer important theoretical basis and practical guidance for improving SMILE surgical techniques and optimizing postoperative management.

02

Conditions studied

  • Small-incision Lenticule Extraction (SMILE) Surgery
  • Corneal Higher-order Wavefront Aberrations
  • Residual Lenticule

Keywords

  • Residual Lenticule
  • Corneal Higher-order Wavefront Aberrations
  • Small-incision Lenticule Extraction
03

In context

Lead sponsor

Second Affiliated Hospital of Nanchang University is the lead sponsor of 85 studies on the registry; 52 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Each subject must have complete surgical video recordings and medical records.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, gender unrestricted;
  2. Equivalent spherical refraction ≤ -10.0D, corrected distance visual acuity ≥ 1.0, myopia stable for ≥ 2 years, and no contact lens wear for at least 2 weeks;
  3. The patient voluntarily participates in this study, signs the form, and agrees to follow up according to the study plan;
  4. Predicted postoperative residual corneal stromal thickness ≥ 280 micrometers.

Exclusion criteria

Exclusion Criteria:

  1. Subclinical keratoconus, keratoconus, moderate to severe corneal opacities or scars, and other ocular conditions;
  2. Diabetes, keloid-prone constitution, and connective tissue diseases, etc.;
  3. Severe mental disorders such as generalized anxiety disorder, panic disorder, depression, schizophrenia, and bipolar disorder; inability to cooperate with physicians;
  4. Refusal to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
33 participants (estimated)
Patient registry
No

Groups and cohorts

  • lenticule retained group
  • Non-lenticule retained group
06

What researchers measure

Primary outcomes

  1. Δ Higher-order Aberration

    Preoperative and postoperative Higher-order aberration difference obtained from wavefront aberrations map of corneal topography in Pentacam measurement.

    Time frame: Day 90

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Feb 3, 2025
StartActual
Oct 31, 2024
Primary completionEst.
Oct 31, 2027was Oct 2026
CompletionEst.
Oct 31, 2027was Oct 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 31, 2026→Oct 31, 2027
Nov 20, 2026
Study completion
Oct 31, 2026→Oct 31, 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Oct 31, 2026→Oct 31, 2027
    Study completion Oct 31, 2026→Oct 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06806085
Lead sponsor
Second Affiliated Hospital of Nanchang University
Responsible party
Jian Xiong (Associate research fellow; Attending physician, Second Affiliated Hospital of Nanchang University) — Principal investigator
First posted
Feb 3, 2025
Start date
Oct 31, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Jian Xiong, doctor
Contact
894040417@qq.com
+8618170906556
Fu Gui, docter
Contact
564436578@qq.com
+861387910191

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion